Forty-percent of patients with HR + HER2- breast cancer harbor activating mutations in the PIK3CA gene, inducing hyperactivation of the alpha-isoform (p110α) of phosphatidylinositol 3-kinase (PI3K) [6]. This evidence concerns the gene ERBB2 and breast cancer.